The CD45 77C/G allele is not associated with myasthenia gravis - a reassessment of the potential role of CD45 in autoimmunity

Table 1 Results of CD45 77C/G genotyping in myasthenia gravis patients and subgroups.

MG patients	n	G	C	MAF	p-val uncorrected	p-val corrected	OR	95% confidence interval for OR	Power (%)^b
All patients	446	17	875	0.019	0.199	-	1.42	0.83-2.45	>99
Female	268	9	527	0.017	0.532	1.000	1.25	0.62-2.53	>99
Male	175	8	342	0.023	0.151	0.302	1.71	0.81-3.61	96
EOMG^a (age of onset ≤40)	208	9	407	0.022	0.176	0.352	1.62	0.80-3.28	98
LOMG^a (age of onset >50)	179	5	353	0.014	0.936	1.000	1.04	0.41-2.60	96
Hyperplasia	161	6	316	0.019	0.442	1.000	1.39	0.60-3.24	93
Thymoma	54	3	105	0.028	0.207	0.621	2.09	0.65-6.78	<70
Normal Thymus	60	2	118	0.017	0.764	1.000	1.24	0.30-5.14	<70
Ocular	42	1	83	0.012	0.902	1.000	0.88	0.12-6.44	<70
Generalized	289	13	565	0.022	0.087	0.260	1.69	0.92-3.09	>99
Severe disease	114	3	225	0.013	0.969	1.000	0.98	0.34-3.14	79
Anti-AChR ab. negative	54	3	105	0.028	0.207	0.414	2.09	0.65-6.78	<70
Anti-AChR ab. positive	389	14	764	0.018	0.321	0.642	1.34	0.75-2.41	>99
HLA B8, DR3 (EOMG)	85	3	167	0.018	0.644	1.000	1.32	0.41-4.24	<70
HLA-B7 (LOMG)	55	1	109	0.009	0.693	1.000	0.67	0.09-4.89	<70
HLA-DR2 (LOMG)	62	1	123	0.008	0.605	1.000	0.60	0.08-4.33	<70
Controls	2303	62	4544	0.013

Allele frequencies for patients and subgroups are given as well as uncorrected and corrected p-values of the 77C/G polymorphism association with the disease. A Bonferroni correction was applied to subgroups based on the number of independent samples in each.
^a EOMG and LOMG patients were anti-AChR antibody positive without the presence of thymoma
^b The power of each group/subgroup comparison to detect the minimum allelic OR (4.53) from all studies reporting a significant association of the SNP to a disorder (Vogel, et. al., 2003, Table 2), at a significance level of 0.05.

ISSN: 1756-0500